FDA approval of pembrolizumab marks major shift in head and neck cancer treatment
Pembrolisabeb, an immune checkpoint inhibitor, has been approved by the US Food and Drug Administration (FDA) for the treatment of patients with advanced head and neck squamous cell carcinoma, whose tumors express PD-L1, whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] As determined by a test approved by the FDA. FDA Approval Pivotle Keenote-689 […]
